Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chidamide + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone + PD-1 inhibitor
- Development stage
- Unknown
- Lead developer
- Ruijin Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
CR-CHOP + PD1 inhibitor is an experimental combination regimen being evaluated for the treatment of newly diagnosed double-expressor diffuse large B-cell lymphoma (DEL DLBCL). The regimen consists of the CR-CHOP backbone—which combines the oral Class I and IIb histone deacetylase (HDAC) inhibitor chidamide (tucidinostat) with the standard-of-care R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)—plus an unspecified PD-1 inhibitor. Chidamide acts as an epigenetic modulator to potentially sensitize lymphoma cells to chemotherapy and immunotherapy. The addition of a PD-1 inhibitor aims to overcome immune evasion in DEL DLBCL, a subtype characterized by MYC and BCL2 co-expression and poor prognosis. This regimen is currently being studied in a molecularly stratified Phase II trial (NCT06701357) sponsored by Ruijin Hospital.
- Other names
- Chidamide plus R-CHOP plus PD-1 inhibitortucidinostat + R-CHOP + PD-1 inhibitor
02
Targets
CD20 (B-lymphocyte antigen CD20)PDCD1 (Programmed cell death protein 1 receptor)HDAC10 (Histone Deacetylase 10)HDAC1 (Histone Deacetylase 1)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on chidamide + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone + PD-1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chidamide + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone + PD-1 inhibitor.